Monitoring response to treatment in asthma management: Food for thought

Clinical and Experimental Allergy

Volumn 34, Issue 8, 2004, Pages 1168-1177

  Scichilone, N ^a,e   Deykin, A ^b   Pizzichini, E ^c   Bellia, V ^a   Polosa, R ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CATANIA   (Italy)

^e Ist di Med Generale e Pneumologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; METHACHOLINE; NITRIC OXIDE; PREDNISONE; STEROID;

ASTHMA; BRONCHUS HYPERREACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; HEALTH CARE; HUMAN; IMMUNOTHERAPY; MEDICAL ASSESSMENT; PATIENT MONITORING; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SENSITIVITY AND SPECIFICITY; SPIROMETRY; SPUTUM ANALYSIS; TREATMENT OUTCOME;

ASTHMA; BREATH TESTS; BRONCHI; BRONCHIAL PROVOCATION TESTS; CHRONIC DISEASE; HUMANS; LUNG; PEAK EXPIRATORY FLOW RATE; QUALITY OF LIFE; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY; SPIROMETRY; SPUTUM; TREATMENT OUTCOME;

EID: 4143065740     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02020.x     Document Type: Review

References (129)

1. Janson C, Anto J, Burney P et al. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J 2001; 18:598-611.
2. Sullivan S, Weiss K. Assessing cost-effectiveness in asthma care building an economic model to study the impact of alternative intervention strategies. Allergy 1993; 48:146-52.
3. Liard R, Leynaert B, Zureik M, Beguin F-X, Neukirch F. Using global initiative for asthma guidelines to assess asthma severity in populations. Eur Respir J 2000; 16:615-20.
4. Boulet L, Becker A, Berube D, Ernst P, Beverdige R. 1998 Revision of the Canadian Asthma Consensus Guidelines. Asthma Consensus Conference Editorial Committee. Can Respir J 1999; 6:231-2.
5. National Institutes of Health NH, Lung and Blood Institute., Guidelines for the diagnosis and management of asthma: National Institutes of Health, National Heart, Lung and Blood Institute; May 1997. Report No.: NIH Publication No. 97-4051A.
6. NAEPP. National Asthma Education and Prevention Program., Expert Panel Report 2. Guidelines for the diagnosis and management of asthma: NIH Publication No. 97-4051; 1997.
7. ATS. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056-61.
8. Djukanovic R, Wilson J, Britten K et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-74.
9. Djukanovic R, Homeyard S, Gratziou C et al. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am Rev Respir Dis 1997; 136:379-83.
10. Gibson P, Wlodarczyk J, Hensley M et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med 1998; 158:36-41.
11. Rytila P, Metso T, Heikkinen K, Saarelainen P, Helenius I, Haahtela T. Airway inflammation in patients with symptoms suggesting asthma but with normal lung function. Eur Respir J 2000; 16:824-30.
12. Crimi E, Balbo A, Milanese M, Miadonna A, Rossi G, Brusasco V. Airway inflammation and occurrence of delayed bronchoconstriction in exercise-induced asthma. Am Rev Respir Dis 1992; 146:507-12.
13. Bousquet J, Jeffery P, Busse W, Johnson M, Vignola A. From bronchoconstriction to airways inflammation and remodeling (state of the art). Am J Respir Crit Care Med 2000; 161:1720-45.
14. Alvarez MJ, Olaguibel JM, Garcia BE, Rodriquez A, Tabar AI, Urbiola E. Airway inflammation in asthma and perennial allergic rhinitis. Relationship with nonspecific bronchial responsiveness and maximal airway narrowing. Allergy 2000; 55:355-62.
15. Woodruff P, Khashayer R, Lazarus S et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001; 108:753-8.
16. De Sanctis G, MacLean J, Mehta S et al. Contribution of nitric oxide synthases 1, 2, and 3 to airway hyperresponsiveness and inflammation in a murine model of asthma. J Exp Med 1999; 189:1621-9.
17. Oderra S, Silvestri M, Penna R, Galeazzi G, Crimi E, Rossi G. Airway eosinophilic inflammation and bronchial hyperresponsiveness after allergen inhalation challenge in asthma. Lung 1998; 176:237-47.
18. Ichinose M, Takahashi T, Sugiura H et al. Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and airway calibre. Eur Respir J 2000; 15:248-53.
19. Laprise C, Laviolette M, Boutet M, Boulet L-P. Asymptomatic airway hyperresponsiveness: relationships with airway inflammation and remodelling. Eur Respir J 1999; 14:63-73.
20. Pattemore P, Asher M, Harrison A, Mitchell E, Rea H, Stewart A. The interrelationship among bronchial hyperresponsiveness, the diagnosis of asthma, and asthma symptoms. Am Rev Respir Dis 1990; 142:549-54.
21. van den Toorn L, Prins J-B, Overbeek S, Hoogsteden N, de Jongste J. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162:953-7.
22. Chai H, Purcell K, Brady K, Falliers CJ. Therapeutic and investigational evaluation of asthmatic children. J Allergy 1968; 41:23-36.
23. Roche W. Inflammatory and structural changes in the small airways in bronchial asthma. Am J Respir Crit Care Med 1998; 157 (Suppl.):S191-4.
24. Woolcock AJ. Effect of drugs on small airways. Am J Respir Crit Care Med 1998; 157 (5 Part 2):S203-7.
25. Jeffery P. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164:528-38.
26. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147:405-10.
27. Macklem P. The physiology of small airways. Am J Respir Crit Care Med 1998; 157:S181-83.
28. Stanescu D. Small airways obstruction syndrome. Chest 1999; 116:231-3.
29. Scichilone N, Permutt S, Togias A. The lack of the bronchoprotective and not the bronchodilatory ability of deep inspiration is associated with airways hyperresponsiveness. Am J Respir Crit Care Med 2001; 163:413-9.
30. Scichilone N, Kapsali T, Permutt S, Togias A. Deep inspiration-induced bronchoprotection is stronger than bronchodilation. Am J Respir Crit Care Med 2000; 162:910-6.
31. Skloot G, Permutt S, Togias A. Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. J Clin Invest 1995; 96:2393-403.
32. Brusasco V, Crimi E, Barisione G, Spanevello A, Rodarte J, Pellegrino R. Airway responsiveness to methacholine: effects of deep inhalations and airway inflammation. J Appl Physiol 1999; 87:567-73.
33. Sundblad BM, Larsson K. Effect of deep inhalations after a bronchial methacholine provocation in asthmatic and non-asthmatic subjects. Respir Med 2002; 96:477-81.
34. Scichilone N, Marchese R, Minà C et al. Asthma severity is related to the bronchodilatory effect of deep inspiration (DI). Am J Respir Crit Care Med 2003; 167:A181.
35. Quackenboss JJ, Lebowitz MD, Krzyzanowski M. The normal range of diurnal changes in peak expiratory flow rates. Relationship to symptoms and respiratory disease. Am Rev Respir Dis 1991; 143:323-30.
36. Higgins BG, Britton JR, Chinn S, Cooper S, Burney PG, Tattersfield AE. Comparison of bronchial reactivity and peak expiratory flow variability measurements for epidemiologic studies. Am Rev Respir Dis 1992; 145:588-93.
37. Enright PL, Burchette RJ, Peters JA, Lebowitz MD, McDonnell WF, Abbey DE. Peak flow lability: association with asthma and spirometry in an older cohort. Chest 1997; 112:895-901.
38. Jain P, Kavuru MS, Emerman CL, Ahmad M. Utility of peak expiratory flow monitoring. Chest 1998; 114:861-76.
39. Ryan G, Latimer KM, Dolovich J, Hargreave FE. Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator, and airway calibre. Thorax 1982; 37:423-9.
40. Kerstjens HA, Brand PL, de Jong PM, Koeter GH, Postma DS. Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. Thorax 1994; 49:1109-15.
41. Kunzli N, Stutz EZ, Perruchoud AP et al. Peak flow variability in the SAPALDIA study and its validity in screening for asthma-related conditions. The SPALDIA Team. Am J Respir Crit Care Med 1999; 160:427-34.
42. 1 and peak expiratory flow rates among normal and asthmatic subjects. Thorax 1994; 49:775-80.
43. Ferguson AC. Persisting airway obstruction in asymptomatic children with asthma with normal peak expiratory flow rates. J Allergy Clin Immunol 1988; 82:19-22.
44. Eid N, Yandell B, Howell L, Eddy M, Sheikh S. Can peak expiratory flow predict airflow obstruction in children with asthma? Pediatrics 2000; 105:354-8.
45. Verschelden P, Cartier A, L'Archeveque J, Trudeau C, Malo JL. Compliance with and accuracy of daily self-assessment of peak expiratory flows (PEF) in asthmatic subjects over a three month period. Eur Respir J 1996; 9:880-5.
46. Brusasco V. Usefulness of peak expiratory flow measurements: is it just a matter of instrument accuracy? Thorax 2003; 58:375-6.
47. Brand PL, Duiverman EJ, Waalkens HJ, van Essen-Zandvliet EE, Kerrebijn KF. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax 1999; 54:103-7.
48. Uwyyed K, Springer C, Avital A, Bar-Yishay E, Godfrey S. Home recording of PEF in young asthmatics: does it contribute to management? Eur Respir J 1996; 9:872-9.
49. Lopez-Vina A, del Castillo-Arevalo E. Influence of peak expiratory flow monitoring on an asthma self-management education programme. Respir Med 2000; 94:760-6.
50. Charlton I, Charlton G, Broomfield J, Mullee MA. Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice. BMJ 1990; 301:1355-9.
51. Lowhagen O, Wever AMJ, Lusuardi M et al. The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients. Respr Med 2002; 96:95-101.
52. Goldstein MF, Veza BA, Dunsky EH, Dvorin DJ, Belecanech GA, Haralabatos IC. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001; 119:1001-10.
53. Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. Thorax 1981; 36:575-9.
54. Van Schoor J, Joos G, Pauwels R. Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research. Eur Respir J 2000; 16:514-33.
55. Cockcroft D, Killian D, Mellon J, Hargreave F. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7:235-43.
56. Murray AB, Ferguson AC, Morrison B. Airway responsiveness to histamine as a test for overall severity of asthma in children. J Allergy Clin Immunol 1981; 68:119-24.
57. Godfrey S, Springer C, Bar-Yishay E, Avital A. Cut-off points defining normal and asthmatic bronchial reactivity to exercise and inhalation challenges in children and young adults. Eur Respir J 1999; 14:659-68.
58. Britton J, Tattersfield AE. Does measurement of bronchial hyperreactivity help in the clinical diagnosis of asthma? Eur J Respir Dis 1986; 68:233-8.
59. Burrows B, Sears M, Flanneery E, Herbison G, Holdaway M, Silva P. Relation of the course of bronchial responsiveness from age 9 to age 15 to allergy. Am J Respir Crit Care Med 1995; 152:1302-8.
60. Gautrin D, Lapierre JG, Malo JL, Infante-Rivard C. Airway hyperresponsiveness and symptoms of asthma in a six-year follow-up study of childhood asthma. Chest 1999; 116:1659-64.
61. ATS Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med 2000; 161:309-29.
62. Woolcock AJ, Yan K, Salome CM. Effect of therapy on bronchial hyperresponsiveness in the long-term management of asthma. Clin Allergy 1988; 18:165-76.
63. Josephs L, Gregg I, Mullee M, Holgate S. Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma. Am Rev Respir Dis 1989; 140:350-7.
64. Avital A, Godfrey S, Springer C. Exercise, methacholine, and adenosine 5′-monophosphate challenges in children with asthma: relation to severity of the disease. Pediatr Pulmonol 2000; 30:207-14.
65. Fowler SJ, Dempsey OJ, Sims EJ, Lipworth BJ. Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. Relationship to asthma severity and beta(2)-receptor genotype. Am J Respir Crit Care Med 2000; 162 (4 Part 1): 1318-22.
66. Sont J, Willems L, Bel E et al. Clinical control and histophathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 159:1043-1051.
67. Joos GF, O'Connor B, Anderson SD et al. Indirect airway challenges. Eur Respir J 2003; 21:1050-68.
68. Polosa R, Rorke S, Holgate ST. Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Thorax 2002; 57:649-54.
69. Polosa R, Li Gotti F, Mangano G, Mastruzzo C, Pistorio MP, Crimi N. Monitoring of seasonal variability in bronchial hyperresponsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy. Clin Exp Allergy 2003; 33:873-81.
70. Prosperini G, Rajakulasingam K, Cacciola RR et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol 2002; 110:855-61.
71. Prieto L, Bruno L, Gutierrez V et al. Airway responsiveness to adenosine 5′-monophosphate and exhaled nitric oxide measurements: predictive value as markers for reducing the dose of inhaled corticosteroids in asthmatic subjects. Chest 2003; 124:1325-33.
72. Pizzichini E, Pizzichini M, Efthimiadis A et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154:308-17.
73. Hargreave F, Pizzichini E, Pizzichini M. Assessment of airway inflammation. In: Barnes P, Grunstein M, Leff A, Woolcock A, eds. Asthma, Vol. 2. Philadelphia, PA, USA: Lippincott-Raven, 1997; 1433-50.
74. Efthimiadis A, Spanevello A, Hamid Q et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J 2002; 37 (Suppl.):19s-23s.
75. Kips JC, Inman MD, Jayaram L et al. The use of induced sputum in clinical trials. Eur Respir J 2002; 37 (Suppl.):47s-50s.
76. Pizzichini MM Is sputum eosinophilia a good or poor predictor of benefit from inhaled corticosteroid therapy in asthma? Eur Respir J 2002; 20:1359-61.
77. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
78. Jayaram L, Hussack P, Efthimiadis A et al. The LOMA study: effect on asthma exacerbation in the first year. Am J Respir Crit Care Med 2002; 167:976.
79. Chlumsky J. Monitoring sputum eosinophils in long-term treatment of bronchial asthma. Eur Respir J 2002; 20:111s.
80. Pizzichini E, Pizzichini M, Gibson P et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158:1511-7.
81. Brightling CE, Monteiro W, Ward R et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356:1480-5.
82. Pizzichini E, Leigh R, Pizzichini M et al. Sputum eosinophils predicts clinical benefit for inhaled budesonide treatment in patients with COPD. Am J Respir Crit Care Med 2002; 167:A320.
83. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Systems Rev 2000: CD002178.
84. Pizzichini M, Marques L, Menegassi V et al. Severe exacerbation of asthma with or without eosinophilic bronchitis: clinical response to oral steroid. Am J Respir Crit Care Med 2002; 167:A767.
85. Lemiere C, Pizzichini M, Balkissoon R et al. Diagnosing occupational asthma: use of induced sputum. Eur Respir J 1999; 13:482-8.
86. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 1991; 181:852-7.
87. Alving K, Weitzberg E, Lundberg J. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1983; 6:1368-70.
88. Kharitonov S, Yates D, Robbins R, Logan-Sinclair R, Shinebourne E, Barnes P. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343:133-5.
89. Massaro A, Gaston B, Kita D, Fanta C, Stamler J, Drazen J. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 1995; 152:800-3.
90. Persson MG, Zetterstrom O, Agrenius V, Ihre E, Gustafsson LE. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet 1994; 343:146-7.
91. Lim S, Jatakanon A, Meah S, Oates T, Chung K, Barnes P. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax 2000; 55:184-8.
92. Kharitonov SA, Yates D, Springall DR et al. Exhaled nitric oxide is increased in asthma. Chest 1995; 107 (Suppl. 3):156S-7S.
93. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53:91-5.
94. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunol Today 1995; 16:128-30.
95. Wechsler M, Grasemann H, Deykin A et al. Exhaled nitric oxide in patients with asthma. Association with NOS1 genotype. Am J Respir Crit Care Med 2000; 162:2043-7.
96. Dupont L, Rochette F, Demedts M, Verleden G. Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma. Am J Respir Crit Care Med 1998; 157:894-8.
97. Chatkin JM, Ansarin K, Silkoff PE et al. Exhaled nitric oxide as a noninvasive assessment of chronic cough. Am J Respir Crit Care Med 1999; 159:1810-3.
98. Deykin A, Massaro AF, Drazen JM, Israel E. Exhaled nitric oxide as a diagnostic test for asthma: online vs. offline techniques and effect of flow rate. Am J Respir Crit Care Med 2002; 165:1597-601.
99. Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 2003; 123:751-6.
100. Puleo PR, Meyer D, Wathen C et al. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med 1994; 331:561-6.
101. Sippel J, Holden W, Tilles S et al. Exhaled nitric oxide levels correlate with measures of disease control in asthma. J Allergy Clin Immunol 2000; 106:645-50.
102. Lanz MJ, Leung DY, White CW. Comparison of exhaled nitric oxide to spirometry during emergency treatment of asthma exacerbations with glucocorticoids in children. Ann Allergy Asthma Immunol 1999; 82:161-4.
103. Crater SE, Peters EJ, Martin ML, Murphy AW, Platts-Mills TA. Expired nitric oxide and airway obstruction in asthma patients with an acute exacerbation. Am J Respir Crit Care Med 1999; 159:806-11.
104. Silkoff PE, Wakita S, Chatkin J et al. Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma. Am J Respir Crit Care Med 1999; 159:940-4.
105. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest 2001; 119:1322-8.
106. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995; 152:609-12.
107. Kharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J 1996; 9:196-201.
108. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996; 153:454-7.
109. Garnier P, Fajac I, Dessanges JF, Dall'Ava-Santucci J, Lockhart A, Dinh-Xuan AT. Exhaled nitric oxide during acute changes of airways calibre in asthma. Eur Respir J 1996; 9:1134-8.
110. Yates D, Kharitonov S, Barnes P. Effect of short-and long-acting inhaled β2-agonists on exhaled nitric oxide in asthmatic patients. Eur Respir J 1997; 10:1483-8.
111. Bratton DL, Lanz MJ, Miyazawa N, White CW, Silkoff PE, Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999; 28:402-7.
112. Bisgaard H, Loland L, Anhoi J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160:1227-31.
113. Payne D, Adcock I, Wilson N, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001; 164:1376-81.
114. Lim S, Jatakanon A, John M et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999; 159:22-30.
115. Lazarus SC, Boushey HA, Fahy JV et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285:2583-93.
116. Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003; 111:256-62.
117. Szefler SJ, Martin RJ, King TS et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-8.
118. Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000; 55:232-4.
119. Jatakanon A, Lim S, Barnes P. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161:64-72.
120. Leuppi J, Salome C, Jenkins C et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163:406-12.
121. Jones S, Kittelson J, Cowan J et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164:738-43.
122. Chervinsky P, van As A, Bronsky EA et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J Allergy Clin Immunol 1994; 94:676-83.
123. Csoma Z, Kharitonov SA, Balint B, Bush A, Wilson NM, Barnes PJ. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2002; 166:1345-9.
124. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166:301-6.
125. Hunt JF, Fang K, Malik R et al. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med 2000; 161 (3 Part 1):694-9.
126. Barley E, Jones P. A comparison of global questions vs. health status questionnaires as measures of the severity and impact of asthma. Eur Respir J 1999; 14:591-6.
127. Bateman ED, Frith LF, Braunstein GL. Achieving guideline-based asthma control: does the patient benefit? Eur Respir J 2002; 20:588-95.
128. Jacobs JE, van de Lisdonk EH, Smeele I, van Weel C, Grol RP. Management of patients with asthma and COPD: monitoring quality of life and the relationship to subsequent GP interventions. Fam Pract 2001; 18:574-80.
129. Bushnell DM, Martin ML, Parasuraman B. Electronic vs. paper questionnaires: a further comparison in persons with asthma. J Asthma 2003; 40:751-62.